The addition of CD20 monoclonal antibodies to lenalidomide improves response rates and survival in relapsed/refractory patients with chronic lymphocytic leukaemia relative to lenalidomide monotherapy - the MD Anderson Cancer Center experience

Philip A. Thompson, Uri Rozovski, Michael J. Keating, Francesco Stingo, Susan C. Smith, William G. Wierda, Lorenzo Falchi, Susan M. O'Brien, Zeev Estrov, Jan A. Burger, Alessandra Ferrajoli

Research output: Contribution to journal › Letter › peer-review

4 Scopus citations

Fingerprint

Dive into the research topics of 'The addition of CD20 monoclonal antibodies to lenalidomide improves response rates and survival in relapsed/refractory patients with chronic lymphocytic leukaemia relative to lenalidomide monotherapy - the MD Anderson Cancer Center experience'. Together they form a unique fingerprint.